SHR-9839 / Jiangsu Hengrui Pharma - LARVOL DELTA

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors (clinicaltrials.gov) - P1/2 | N=60 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1/2 trial • Oncology • Solid Tumor

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov) - P1/2 | N=47 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Enrolling by invitation ➔ Active, not recruiting | N=70 ➔ 47

Enrollment change • Enrollment closed • Oncology • Solid Tumor • KRAS

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=174 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (clinicaltrials.gov) - P1/2 | N=400 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (clinicaltrials.gov) - P1/2 | N=876 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

An exploratory study of HRS-4642 combination therapy for advanced colorectal cancer (ChiCTR) - P1/2 | N=78 | Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

New P1/2 trial • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Hengrui Medicine (600276.SH): New drug clinical trial approved, accelerating layout in the anti-tumor field [Google translation] (Sina Corp) - "On January 16, 2025, Jiangsu Hengrui...announced that its subsidiaries Suzhou Shengdiya Biotechnology Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd. received the 'Drug Clinical Trial Approval Notice' for SHR-A1811 for injection and SHR-9839 for injection approved and issued by the National Medical Products Administration (NMPA), and plan to conduct clinical trials in the near future."

New trial • Solid Tumor

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (clinicaltrials.gov) - P1/2 | N=400 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (clinicaltrials.gov) - P1/2 | N=876 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Combination therapy • New P1/2 trial • Oncology • Solid Tumor

Hengrui Medicine’s innovative drug SHR-1826 for injection in combination with advanced solid tumors is approved for clinical trials [Google translation] (Jiangsu Hengrui Press Release) - "Recently, Hengrui Medicine's subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biotechnology Co., Ltd. received the 'Notice of Approval for Drug Clinical Trials' approved and issued by the National Medical Products Administration, approving the company to conduct a multicenter, open Phase IB/II clinical study on the safety, tolerability and efficacy of SHR-1826 for injection, HRS-4642 injection, adebelimumab injection, SHR-9839 for injection, SHR-8068 injection and bevacizumab injection in subjects with advanced solid tumors."

New P1/2 trial • Solid Tumor

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=156 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Oncology • Solid Tumor

Hengrui Medicine (600276.SH): Clinical trial applications for three drugs from its subsidiary were approved [Google translation] (Sina Corp) - "According to the Zhitong Finance APP...issued an announcement that its subsidiaries Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia , Ltd. received the 'Drug Clinical Trial Approval Notice' approved by the National Medical Products Administration for the issuance of SHR-9839 for injection, SHR-A1921 for injection and SHR-A2009 for injection, and will conduct clinical trials in the near future."

New trial • Oncology • Solid Tumor

Simcere Pharmaceuticals' Phase III study of innovative anti-influenza drug was successful; Junshi Biologics' first-quarter revenue was 380 million yuan [Google translation] (163.com) - "On April 29, according to the CDE official website, Hengrui Medicine’s injection SHR-9839 was approved for clinical use and is planned to be combined with SHR-A2009, or SHR-A1921, or ametinib, or combined with chemotherapy to treat advanced solid tumors...according to the CDE official website, Yangli Pharmaceutical VB15010 tablets were approved for clinical use and plans to conduct research on the treatment of advanced solid tumors....according to the CDE official website, BeiGene’s BGB-A3055 for injection was approved for clinical use and plans to conduct research on the treatment of advanced or metastatic solid tumors."

New trial • Oncology • Solid Tumor

Hengrui Pharmaceutical (600276.SH): HRS-4642 injection and other drugs received drug clinical trial approval notice [Google translation] (Investing.com) - "...Hengrui Pharmaceutical...announced that the company and its subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., and Suzhou Shengdia Biopharmaceutical Co., Ltd. have received notification from the National Medical Products Administration (hereinafter referred to as the National Medical Products Administration). 'State Food and Drug Administration') approved and issued the 'Drug Clinical Trial Approval Notice' for HRS-4642 Injection, Adebrelimab Injection, SHR-A1904 for Injection, SHR-9839 for Injection and SHR-A1921 for Injection 》, clinical trials will be launched in the near future."

New trial • Oncology • Solid Tumor

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=174 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor